The confirmed reconstruction measures include, among other things:

• A directed set-off issue and a rights issue, both to be carried out within two months from the date on which the reconstruction plan became legally binding.
• The directed set-off issue entails that certain creditors, as part of the debt settlement under the reconstruction plan, will set off their claims against newly issued shares in the Company.
• The rights issue will be directed to the Company’s existing shareholders, who will be offered the opportunity to participate in the financing of the Company on equal terms. The rights issue amounts to SEK 15 million, of which subscription commitments and guarantee undertakings shall amount to at least SEK 10 million.
• The issues are conditional upon obtaining necessary permits or confirmations from the Inspectorate of Strategic Products (ISP), as well as exemptions from mandatory bid obligations in accordance with applicable takeover rules for certain trading platforms.
• Payment of the debt settlement shall be made as soon as practically possible following completion of the issues. If the issues have not been completed by the last banking day of the month occurring two months after the reconstruction plan became legally binding, the reconstruction plan shall be deemed forfeited.
• The rights issue comprises a maximum of 93,374,091 units, corresponding to 9,337,409,100 shares and 9,337,409,100 warrants of series TO6. Upon full subscription of the rights issue, Peptonic Medical will receive approximately SEK 14.9 million before issue-related costs, which are estimated to amount to a maximum of approximately SEK 1.7 million.
• The right to subscribe for units in the rights issue with preferential rights shall be granted to shareholders in proportion to the number of shares previously held, whereby one (1) existing share as of the record date on 9 January 2026 entitles the holder to one (1) unit right, and one hundred (100) unit rights entitle the holder to subscribe for one (1) unit. One (1) unit consists of one hundred (100) shares and one hundred (100) warrants of series TO6.
• The subscription price per unit in the rights issue amounts to SEK 0.16, corresponding to SEK 0.0016 per share, as the warrants of series TO6 are issued free of charge.
• The subscription price for shares subscribed for through the exercise of warrants of series TO6 shall amount to seventy (70) percent of the volume-weighted average price of the Company’s share during the period from 18 May 2026 up to and including 29 May 2026, however not lower than the share’s quota value.
• Warrants of series TO6 may be exercised for subscription of new shares during the period from 1 June 2026 up to and including 12 June 2026.
• Full terms and conditions and instructions for the rights issue, as well as additional information about the Company, will be set out in the EU Growth Prospectus that the Company intends to publish.
• The Company intends to revert with further information regarding the timing of the subscription period and the publication of the EU Growth Prospectus.

The implementation of the above measures marks the transition of the reconstruction plan from confirmation to practical execution. The Company thereby enters the next phase of its operations, with full focus on sales growth and financial stability.

The certificate of legal force and all measures included in the reconstruction plan previously communicated are available on the Company’s website:
https://www.peptonicmedical.se/investerare/foretagsrekonstruktion-2025/

For further information, please contact:
 Anna Linton, CEO, Peptonic Medical AB                                                                                                                        Email: anna.linton@peptonicmedical.se                                                                                                                           Phone: +46 70-244 92 07

About Peptonic Medical AB                                                                                                          

Peptonic Medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.